SEC-sourced researchBeta
ENSC
Ensysce Biosciences, Inc.
Company comparison ↗
Data passport
- CIK
- 0001716947
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Sep 29, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 5,210,031.0000 | Mar 30, 2026 |
| December 2025 | 5,066,650.0000 | Mar 30, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 5,066,650.0000 | -10,176,187.0000 | -7,806,292.0000 | 7,452,479.0000 | 4,567,729.0000 | Mar 30, 2026 |
| December 2024 | 5,210,031.0000 | -7,987,009.0000 | -7,502,700.0000 | 5,597,232.0000 | 2,217,293.0000 | Mar 30, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $5.07M | December 2025 | Mar 30, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $5.21M | December 2024 | Mar 30, 2026 | 10-K |
| Net incomeProfitLoss | -$10.18M | December 2025 | Mar 30, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$7.81M | December 2025 | Mar 30, 2026 | 10-K |
| Total assetsAssets | $7.45M | December 2025 | Mar 30, 2026 | 10-K |
| Total liabilitiesLiabilities | $4.57M | December 2025 | Mar 30, 2026 | 10-K |